MedTrace Logo

Evaluating the Effect of Senna in Uremic Pruritus

NCT02008864 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-04-01

No results posted yet for this study

Summary

Uremic pruritus remains one of the most frustrating and potentially disabling symptoms in patients with end stage renal disease. It affect up to 90 percent of patients with end stage renal disease. Several hypotheses have been postulated for the possible underlying etiology, but none is conclusive. Aside from kidney transplantation, which is only definitive treatment, therapeutic approaches have largely been empirical, and no firm evident-base treatments are available. The main goal of therapy remains to minimize severity of pruritus. In Iranian traditional medicine Cassia senna L. is used for healing uremic pruritus . In this study investigators considered to evaluate effect of Cassia senna L. in uremic pruritus by a double blind placebo control clinical trial. It is hypothesized that oral Cassia senna L. may attenuate uremic pruritus by decreasing serum IL-2, IFN-γ and TNF-α.

Conditions

Interventions

DRUG

Senna

(7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day

DRUG

Placebo

Placebo tablet/ 2 times per day

Sponsors & Collaborators

  • Shiraz University of Medical Sciences

    lead OTHER

Principal Investigators

  • Jamshid Roozbeh, MD · Shiraz University of Medical Sciences

  • Abdolali Mohagheghzadeh, PhD · Shiraz University of Medical Sciences

  • Mohammad Mehdi Sagheb, MD · Shiraz University of Medical Sciences

  • Arian Kamali-Sarvestani, Pharm D · Shiraz University of Medical Sciences

  • Pouya Faridi, PhD · Shiraz University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-09-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02008864 on ClinicalTrials.gov